Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Protective Effects of Edaravone Dexborneol

The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol treatment group and edaravone treatment group. The purpose of this study was to observe the changes of

  • 0 views
  • 22 Sep, 2021
  • 1 location
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186

  • 0 views
  • 05 May, 2022
  • 9 locations
Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

This study is a multicentre, randomized, double-blind, placebo parallel controlled, investigator-sponsored study that aims to investigate the efficacy and safety of Edaravone Dexborneol

  • 0 views
  • 06 Apr, 2022
  • 1 location
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating ScaleRevised

primary lateral sclerosis
edaravone
  • 1 views
  • 02 Jun, 2022
  • 94 locations
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension (HIMALAYA)

the study site, region of ALS onset (bulbar vs other areas), use of riluzole (yes vs no), and use of edaravone (yes vs no). Participants will attend inclinic study assessments at baseline (Day 1

primary lateral sclerosis
riluzole
body mass index
edaravone
  • 0 views
  • 15 Sep, 2022
  • 20 locations
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)  

the study site, region of ALS onset (bulbar vs other areas), use of riluzole (yes vs no), and use of edaravone (yes vs no). Participants will attend inclinic study assessments at baseline (Day 1

primary lateral sclerosis
riluzole
body mass index
edaravone
  • 32 views
  • 29 Sep, 2022
  • 28 locations
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

weakness
riluzole
edaravone
primary lateral sclerosis
  • 0 views
  • 11 Aug, 2022
  • 55 locations
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows (EXISTENT)

To explore the safety and efficacy of edaravone dexborneol for patients of acute ischemic stroke received endovascular therapy in extended time windows.

  • 0 views
  • 23 Apr, 2022
  • 1 location
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (PARADIGM)

stratified for ENCALS risk category [high risk ≥ -4.5 vs. low risk < -4.5], and for background ALS treatment (riluzole and/or edaravone and/or sodium phenylbutyrate and/or taurursodiol) vs. no background

riluzole
edaravone
pregnancy testing
weakness
  • 0 views
  • 07 Jul, 2022
  • 1 location
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial (MICABO-ALS)

The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow …

riluzole
vitamin e
primary lateral sclerosis
  • 0 views
  • 21 Apr, 2022
  • 1 location